EGFR and paronychia: Most instances of paronychia related to EGFR TKI therapy are mild, but in clinical trials of afatinib, treatment-related paronychia led to dose reductions in 14% of patients (Melosky & Hirsh, 2014; Boehringer Ingelheim Pharmaceuticals, 2014).